Neurotensinergic neurons are specialized neurons that produce and release neurotensin (NT), a 13-amino acid neuropeptide originally isolated from the bovine hypothalamus in 1973. This neuropeptide acts as both a neuropeptide (released from dense core vesicles) and a neuromodulator (modulating GABAergic and dopaminergic transmission), playing crucial roles in pain modulation, dopamine signaling, neuroprotection, and various neuropsychiatric processes. Neurotensinergic neurons are distributed throughout the central nervous system, with particularly high concentrations in the hypothalamus, substantia nigra, ventral tegmental area, and central gray matter[@tylermcmahon2000][@stalla2010].
Neurotensin interacts with two G protein-coupled receptors: NTS1 (high-affinity, signal transduction through Gq/11) and NTS2 (lower-affinity, signaling through Gi/o). A third receptor, NTS3 (also called sortilin), functions as a neurotensin clearance receptor. The distribution of these receptors in the brain closely matches the locations of neurotensinergic neurons, enabling precise paracrine and autocrine signaling.
¶ Peptide Structure and Processing
Neurotensin is synthesized as a larger precursor (pre-neurotensin/neuromedin N precursor) and processed into multiple forms:
| Form |
Length |
Function |
| Neurotensin (NT) |
13 aa |
Primary active form |
| Neurotensin(1-8) |
8 aa |
N-terminal fragment, active |
| Neuromedin N |
13 aa |
Related peptide, same precursor |
- Affinity: KD ~ 0.1 nM
- G Protein: Gq/11 → PLC → IP3/DAG → Ca2+ mobilization
- Signaling: PKC activation, MAPK pathways
- Desensitization: GRK-mediated phosphorylation
- Affinity: KD ~ 5-10 nM
- G Protein: Gi/o → inhibition of adenylate cyclase
- Signaling: Modulation of neuronal excitability
- Distribution: Broader than NTS1
- Function: Clearance and transport
- Role: Modulates NT availability
- Pathology: Implicated in neurodegenerative diseases
| Region |
Density |
Function |
| Hypothalamus (periventricular, arcuate) |
High |
Neuroendocrine regulation |
| Substantia Nigra (pars compacta) |
High |
Modulation of dopamine neurons |
| Ventral Tegmental Area |
High |
Reward and motivation |
| Central Gray Matter |
Moderate |
Pain modulation |
| Bed Nucleus of Stria Terminalis |
Moderate |
Stress response |
| Amygdala |
Moderate |
Emotional processing |
| Prefrontal Cortex |
Low |
Cognitive modulation |
Neurotensinergic neurons project to:
- Substantia Pars Compacta → Modulates dopaminergic neuron firing
- Ventral Tegmental Area → Influences mesolimbic dopamine pathways
- Striatum → Direct modulation of motor control circuits
- Hippocampus → Memory and plasticity modulation
- Cortex → Cognitive and attentional functions
Neurotensin powerfully modulates dopaminergic transmission:
- D1 Modulation: NT enhances D1 receptor-mediated signaling
- D2 Modulation: NT attenuates D2 receptor function
- Firing Patterns: NT increases burst firing of dopamine neurons
- Terminal Release: NT modulates dopamine release in striatum
- Reward Circuitry: NT in VTA links to reward processing
- Motivation: Modulates approach behavior and motivation
- Addiction: NT signaling altered in addiction models
Neurotensin has complex effects on pain processing:
- Analgesic Effects: NT produces potent analgesia through NTS1
- Peripheral Effects: NT in peripheral nerve endings modulates nociception
- ** Spinal Cord**: NT in dorsal horn modulates pain transmission
- Descending Pathways: NT in PAG-RVM system mediates analgesia[@dubois2021]
- Pituitary Regulation: NT affects ACTH, prolactin, growth hormone
- Thermoregulation: NT influences body temperature
- Food Intake: NT has anorexigenic effects
- Water Balance: NT modulates thirst
- Blood Pressure: NT has vasoactive effects
- GI Motility: NT affects gastric acid secretion and motility
- Immunomodulation: NT influences immune responses
Neurotensin provides significant neuroprotection for dopaminergic neurons:
- Anti-apoptotic Effects: NT activates pro-survival signaling (PI3K/Akt, MAPK)
- Mitochondrial Protection: NT preserves mitochondrial function
- Anti-oxidant: NT reduces oxidative stress
- Anti-inflammatory: NT modulates microglial activation[@liu2019]
- Endogenous Protection: NT normally protects dopamine neurons
- PD Pathology: NT expression/signaling altered in PD
- NTS1 Agonists: NTS1 activation provides neuroprotection
- Combination Therapy: NT agonists + dopaminergic drugs
- CSF NT levels may serve as a biomarker in PD
- NTergic dysfunction contributes to non-motor symptoms
- Targeting NT system may slow disease progression
Neurotensin signaling is altered in AD:
- Amyloid Effects: Aβ alters NT expression and release
- Cholinergic Interaction: NT modulates cholinergic system
- Memory Functions: NT affects hippocampal plasticity
- Therapeutic Targeting: NT agonists under investigation
¶ Schizophrenia and Bipolar Disorder
NT is heavily implicated in psychosis:
- Dopamine Hypothesis Interaction: NT modulates dopamine, linking to psychosis
- NT Deficiency: Reduced NT in brain and CSF of schizophrenic patients
- Antipsychotic Effects: Many antipsychotics increase NT levels
- Biomarker Potential: CSF NT as state marker[@toth2013][@caceda2006]
- Depression: NT alterations in depressive disorders
- Anxiety: NT in stress and anxiety responses
- Autism: NT signaling differences in ASD
- Epilepsy: NT has anti-seizure effects
- Pain: NTS1 agonists as non-opioid analgesics
- Obesity: NT reduces food intake and body weight
- Neuroprotection: PD and AD therapeutic potential
- Schizophrenia: May have antipsychotic effects
- AB-111: NTS1 agonist in development for schizophrenia
- PD-168077: NTS1 agonist with neuroprotective effects
- Compound 21: NTS1 agonist for analgesia
- NTS2 Antagonists: Potential for anxiety disorders
- Dual Antagonists: Combined NTS1/2 targeting
- Clinical Trials: Limited, largely preclinical
¶ Gene and Cell-Based Therapies
- Gene Delivery: Viral vector-mediated NT expression
- Cell Transplantation: NT-producing cell grafts
- Peptide Delivery: NT analogs with improved stability
- CSF NT Levels: Diagnostic and prognostic marker
- Peripheral Measurements: Blood NT as accessible biomarker
- Imaging: NTSR PET ligands in development[@kumar2017]
- Neurotensin: role as a modulator of dopaminergic transmission (2000). Progress in Drug Research.
- Neurotensin in the CNS: biological actions and therapeutic potential (2010). Cell Tissue Res.
- Neurotensin and dopamine interactions in neuropsychiatric diseases (2018). J Neurosci Res.
- Neurotensin and neuroprotection in Parkinson's disease (2019). Neurobiol Aging.
- Neurotensin and pain modulation (2021). Pain.
- Neurotensin in schizophrenia and bipolar disorder (2013). Prog Neuropsychopharmacol.
- Neurotensin: role in psychiatric and neurological diseases (2006). Peptides.
- Neurotensin receptor agonists for obesity (2019). Nat Rev Drug Discov.
- CSF neurotensin as biomarker (2017). J Neurol.
- Antipsychotic drug development: role of neurotensin (2010). Trends Pharmacol Sci.
- Tyler-McMahon BM, Boules M, Richelson E, Neurotensin: role as a modulator of dopaminergic transmission (2000)
- Stalla GK, Loidl P, Uhl E, et al, Neurotensin in the central nervous system: biological actions and therapeutic potential (2010)
- Katsurd N, Bhardwaj S, Huang W, et al, Neurotensin and dopamine interactions in neuropsychiatric diseases (2018)
- Liu Y, Cheng J, Ouyang Q, et al, Neurotensin and neuroprotection in Parkinson's disease (2019)
- Dubois M, Emond S, Bernard V, et al, Neurotensin and pain modulation (2021)
- Toth K, Loven T, Nuss J, et al, Neurotensin in schizophrenia and bipolar disorder (2013)
- Caceda R, Kinkead B, Nemeroff CB, Neurotensin: role in psychiatric and neurological diseases (2006)
- Muller TD, Culler M, Esser J, et al, Neurotensin receptor agonists for obesity treatment (2019)
- Kumar R, Tripathi M, Ahmad M, et al, CSF neurotensin as biomarker in neurodegenerative diseases (2017)
- Richardson PJ, Kase H, Jenner PG, Antipsychotic drug development: the role of neurotensin (2010)